Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Receivables - Net (2016 - 2025)

Coherus Oncology's Receivables - Net history spans 12 years, with the latest figure at $17.8 million for Q4 2025.

  • For Q4 2025, Receivables - Net fell 84.0% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $17.8 million, down 84.0%, while the annual FY2025 figure was $17.8 million, 84.0% down from the prior year.
  • Receivables - Net for Q4 2025 was $17.8 million at Coherus Oncology, up from $9.2 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $260.5 million in Q4 2023 and bottomed at $5.1 million in Q2 2025.
  • The 5-year median for Receivables - Net is $120.0 million (2021), against an average of $124.7 million.
  • The largest annual shift saw Receivables - Net skyrocketed 148.33% in 2024 before it plummeted 97.08% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $123.0 million in 2021, then fell by 10.61% to $110.0 million in 2022, then skyrocketed by 136.92% to $260.5 million in 2023, then tumbled by 57.27% to $111.3 million in 2024, then plummeted by 84.0% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Receivables - Net are $17.8 million (Q4 2025), $9.2 million (Q3 2025), and $5.1 million (Q2 2025).